An important future direction will be to further improve uponthe relatively modest therapeutic efficacy of the vaccine; for example,through optimization of dose and regimen, combination with immunomodulatorsthat reprogram the tumor microenvironment, addition of CD4+ T cell helper epitopes, and/or incorporation of additional neoantigenicpeptides. The gene discussed is CD4; the disease is neoplasm.